Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,421 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin-to-skin Clear all
Completed No phase listed Observational

The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment

NCT06096623
View directory record Official record
Conditions
Cancer, Breast Cancer, Colorectal Cancer
Interventions
Weekly Survey
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

NCT01060670
View directory record Official record
Conditions
Neuropathic Diabetic Ulcer - Foot
Interventions
Integra® Dermal Regeneration Template, Conventional Wound Therapy
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
32
States / cities
Mobile, Alabama • Bakersfield, California • Castro Valley, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 1 Interventional Results available

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

NCT02063724
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2 pulsed Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Michigan Genetic Hereditary Testing (MiGHT)

NCT05162846
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
Interventions
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
Other · Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris

NCT03303170
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles, Nd:Yag Laser
Device
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Safety and Efficacy of Micro-coring Device for Treatment of Facial Wrinkles and Skin Laxity

NCT03228641
View directory record Official record
Conditions
Wrinkle, Facial and Neck Skin Laxity
Interventions
micro-excisional skin removal with coring needle
Device
Lead sponsor
Cytrellis Biosystems, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
6
States / cities
Sacramento, California • Miami, Florida • Chestnut Hill, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis

NCT03538951
View directory record Official record
Conditions
Actinic Keratosis
Interventions
10% VDA-1102, 20% VDA-1102
Drug
Lead sponsor
Vidac Pharma
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

NCT05031494
View directory record Official record
Conditions
Melanoma, Pancreatic Ductal Adenocarcinoma
Interventions
YH003, Toripalimab, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Eucure (Beijing) Biopharma Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 4 Interventional Results available

Mechanism of Action Study for Psoriasis

NCT00932113
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate, Adalimumab (Humira)
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults

NCT00119379
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
NucleomaxX, Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 9, 2026, 1:58 AM EDT
Completed No phase listed Observational

Pancreatic Cancer Early Detection Program

NCT02206360
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer, BRCA 1/2, HNPCC, Lynch Syndrome, Hereditary Pancreatitis, FAMMM, Familial Atypical Multiple Mole Melanoma, Peutz Jeghers Syndrome
Interventions
Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
White Plains Hospital
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

NCT02230566
View directory record Official record
Conditions
MPS 7, Sly Syndrome, Mucopolysaccharidosis, MPS VII
Interventions
UX003, Placebo
Drug · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Oakland, California • Orange, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion

NCT05036083
View directory record Official record
Conditions
Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Contrast-Enhanced Mammography, Digital Tomosynthesis Mammography, Electronic Health Record Review, Iodinated Contrast Agent
Procedure · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

NCT00292422
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Lansing, Michigan • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2007 · Synced Oct 9, 2026, 1:58 AM EDT
Completed No phase listed Observational

Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening

NCT03372902
View directory record Official record
Conditions
Breast Cancer, Breast Benign
Interventions
Breast MRI, Breast Mammogram, Blood draw, Breast Biopsy, online participant reported questionnaire
Device · Other · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
7
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 9, 2026, 1:58 AM EDT
Completed No phase listed Observational

Implementation of a Web-based Decision Aid for Breast Cancer Surgery

NCT03304002
View directory record Official record
Conditions
Breast Cancer, Surgery
Interventions
Breast Cancer Surgery Decision Aid
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 9, 2026, 1:58 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 9, 2026, 1:58 AM EDT
Terminated Phase 2 Interventional

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

NCT01026051
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma
Interventions
MKC1106-MT
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Stuart, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

NCT03248531
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 9, 2026, 1:58 AM EDT
Not listed Phase 3 Interventional Results available

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
3,966 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
777
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 523 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02586805
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 9, 2026, 1:58 AM EDT
Recruiting No phase listed Observational

Genetic Analysis of Keloids

NCT01619553
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
Not listed
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

NCT05593445
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 9, 2026, 1:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

NCT06103877
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1163, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 9, 2026, 1:58 AM EDT